BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 38072070)

  • 1. Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.
    Manolis A; Kallistratos M; Poulimenos L; Thomopoulos C
    Am J Med Sci; 2024 Mar; 367(3):155-159. PubMed ID: 38072070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the Antianginal Drugs Ranolazine, Nicorandil, and Ivabradine on Coronary Microvascular Function in Patients With Nonobstructive Coronary Artery Disease: A Meta-analysis of Randomized Controlled Trials.
    Zhu H; Xu X; Fang X; Zheng J; Zhao Q; Chen T; Huang J
    Clin Ther; 2019 Oct; 41(10):2137-2152.e12. PubMed ID: 31548105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of Angina: Where Are We?
    Balla C; Pavasini R; Ferrari R
    Cardiology; 2018; 140(1):52-67. PubMed ID: 29874661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ranolazine and Ivabradine: two different modalities to act against ischemic heart disease.
    Cacciapuoti F
    Ther Adv Cardiovasc Dis; 2016 Apr; 10(2):98-102. PubMed ID: 26944071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New Anti-Anginal Drugs: Ranolazine.
    Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.
    Rosano GMC; Vitale C; Volterrani M
    Cardiovasc Drugs Ther; 2016 Aug; 30(4):393-398. PubMed ID: 27417323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic approaches to treating chronic angina in the setting of chronic ischemic heart disease.
    Chaitman BR; Sano J
    Clin Cardiol; 2007 Feb; 30(2 Suppl 1):I25-30. PubMed ID: 18373327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
    Yuriivna Osovska N; Vitaliivna Kuzminova N
    Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial.
    Chaitman BR; Pepine CJ; Parker JO; Skopal J; Chumakova G; Kuch J; Wang W; Skettino SL; Wolff AA;
    JAMA; 2004 Jan; 291(3):309-16. PubMed ID: 14734593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable angina pectoris: current medical treatment.
    Siama K; Tousoulis D; Papageorgiou N; Siasos G; Tsiamis E; Bakogiannis C; Briasoulis A; Androulakis E; Tentolouris K; Stefanadis C
    Curr Pharm Des; 2013; 19(9):1569-80. PubMed ID: 23016717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antianginal Therapy for Stable Ischemic Heart Disease: A Contemporary Review.
    Padala SK; Lavelle MP; Sidhu MS; Cabral KP; Morrone D; Boden WE; Toth PP
    J Cardiovasc Pharmacol Ther; 2017 Nov; 22(6):499-510. PubMed ID: 28361599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional and novel drug therapeutics to relief myocardial ischemia.
    Dvir D; Battler A
    Cardiovasc Drugs Ther; 2010 Aug; 24(4):319-23. PubMed ID: 20658184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ranolazine: effects on ischemic heart.
    Rognoni A; Barbieri L; Cavallino C; Bacchini S; Veia A; Degiovanni A; Rametta F; Nardi F; Lazzero M; Lupi A; Bongo AS
    Recent Pat Cardiovasc Drug Discov; 2013 Dec; 8(3):197-203. PubMed ID: 23961914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-haemodynamic anti-anginal agents in the management of patients with stable coronary artery disease and diabetes: A review of the evidence.
    Ambrosio G; Tamargo J; Grant PJ
    Diab Vasc Dis Res; 2016 Mar; 13(2):98-112. PubMed ID: 26873904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the management of chronic stable angina II. Anti-ischemic therapy, options for refractory angina, risk factor reduction, and revascularization.
    Kones R
    Vasc Health Risk Manag; 2010 Sep; 6():749-74. PubMed ID: 20859545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-anginal drugs-beliefs and evidence: systematic review covering 50 years of medical treatment.
    Ferrari R; Pavasini R; Camici PG; Crea F; Danchin N; Pinto F; Manolis A; Marzilli M; Rosano GMC; Lopez-Sendon J; Fox K
    Eur Heart J; 2019 Jan; 40(2):190-194. PubMed ID: 30165445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study.
    Melloni C; Newby LK
    Expert Rev Cardiovasc Ther; 2008 Jan; 6(1):9-16. PubMed ID: 18095903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranolazine: a review of its use in chronic stable angina pectoris.
    Siddiqui MA; Keam SJ
    Drugs; 2006; 66(5):693-710. PubMed ID: 16620147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranolazine in patients with angina and coronary artery disease.
    Scirica BM; Morrow DA
    Curr Cardiol Rep; 2007 Jul; 9(4):272-8. PubMed ID: 17601393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ranolazine: a review of its use in chronic stable angina pectoris.
    Keating GM
    Drugs; 2008; 68(17):2483-503. PubMed ID: 19016575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.